Redeye comments on results from the recent BE study with generic HyNap Dasa. Once again, BE was not met, and the share traded down some 30% on the announcement. We consider this an overreaction and believe Xspray fundamentally undervalued at these price levels. With that said, Xspray will have to deliver good news for the share to rebound, we judge.